THX Pharma (STU:3VG) Beginning Cash Position: €2.12 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3VG THX Pharma STU:3VG
37 GF Score
Price €3.65
! 1 Warning Sign
View Full Analysis

What is THX Pharma Beginning Cash Position?

THX Pharma STU:3VG -0.41% 37 Beginning Cash Position is €2.12 Mil as of Dec. 2025. GuruFocus rates STU:3VG with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

THX Pharma's Beginning Cash Position for the quarter that ended in Dec. 2025 was €2.12 Mil.

THX Pharma's quarterly Beginning Cash Position declined from Dec. 2024 (€1.75 Mil) to Jun. 2025 (€0.97 Mil) but then increased from Jun. 2025 (€0.97 Mil) to Dec. 2025 (€2.12 Mil).

THX Pharma's annual Beginning Cash Position declined from Dec. 2023 (€9.15 Mil) to Dec. 2024 (€4.91 Mil) and declined from Dec. 2024 (€4.91 Mil) to Dec. 2025 (€0.97 Mil).

THX Pharma Beginning Cash Position Related Terms

THX Pharma Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for THX Pharma's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

THX Pharma Beginning Cash Position Chart

THX Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.21 12.53 9.15 4.91 0.97

THX Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.78 4.91 1.75 0.97 2.12
STU:3VG
37GF Score
THX Pharma STU:3VG
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

THX Pharma Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €2.12 Mil mean?
THX Pharma (STU:3VG) has a Beginning Cash Position of €2.12 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on THX Pharma and its competitors.
Is THX Pharma's Beginning Cash Position too high?
THX Pharma's current Beginning Cash Position is €2.12 Mil. Overall, THX Pharma has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's Beginning Cash Position compare to VRTX and REGN?
THX Pharma's Beginning Cash Position of €2.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on THX Pharma and its competitors. THX Pharma's current Beginning Cash Position is €2.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (STU:3VG) has a current Beginning Cash Position of €2.12 Mil. The current Beginning Cash Position is €2.12 Mil. THX Pharma's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For THX Pharma (STU:3VG), the current Beginning Cash Position is €2.12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

THX Pharma Business Description

Other Exchanges ALTHX:France
Address 60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
37GF Score

Get the complete analysis for STU:3VG

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.65
Price